Eosinophils: Multifaceted biological properties and roles in health and disease

Immunological Reviews

Volumn 242, Issue 1, 2011, Pages 161-177

  Kita, Hirohito ^a  

^a MAYO CLINIC   (United States)

Author keywords

Eosinophils; Humans; Hypersensitivity; Inflammation; Mice

Indexed keywords

ALPHA INTERFERON; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYTOKINE; EOSIN; EOSINOPHIL GRANULE PROTEIN; GLUCOCORTICOID; INTERLEUKIN 5 ANTIBODY; LIPID;

ADAPTIVE IMMUNITY; ANTIGEN SPECIFICITY; ARTICLE; ASTHMA; BONE MARROW; EOSINOPHIL; EOSINOPHILIA; EOSINOPHILIC ESOPHAGITIS; GASTROINTESTINAL TRACT; HOMEOSTASIS; HUMAN; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; MAMMARY GLAND; MEMORY T LYMPHOCYTE; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; STAINING; TH2 CELL;

ADAPTIVE IMMUNITY; ADULT; ANIMALS; CELL MOVEMENT; CYTOKINES; EOSINOPHIL GRANULE PROTEINS; EOSINOPHILS; HOMEOSTASIS; HUMANS; HYPERSENSITIVITY; IMMUNITY, INNATE; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, TRANSGENIC; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY; TH2 CELLS;

EID: 79959353756     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2011.01026.x     Document Type: Article

References (201)

1. Gleich GJ, Adolphson CR. The eosinophilic leukocyte: structure and function. Adv Immunol 1986;39:177-253.
2. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol 2006;24:147-174.
3. Hogan SP, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 2008;38:709-750.
4. McNagny K, Graf T. Making eosinophils through subtle shifts in transcription factor expression. J Exp Med 2002;195:F43-F47.
5. Walsh JC, et al. Cooperative and antagonistic interplay between PU.1 and GATA-2 in the specification of myeloid cell fates. Immunity 2002;17:665-676.
6. Du J, et al. Novel combinatorial interactions of GATA-1, PU.1, and C/EBPepsilon isoforms regulate transcription of the gene encoding eosinophil granule major basic protein. J Biol Chem 2002;277:43481-43494.
7. Yu C, et al. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med 2002;195:1387-1395.
8. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood 1992;79:3101-3109.
9. Mishra A, Hogan SP, Lee JJ, Foster PS, Rothenberg ME. Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest 1999;103:1719-1727.
10. Humbles AA, et al. The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc Natl Acad Sci USA 2002;99:1479-1484.
11. Pope SM, et al. Identification of a cooperative mechanism involving interleukin-13 and eotaxin-2 in experimental allergic lung inflammation. J Biol Chem 2005;280:13952-13961.
12. Gouon-Evans V, Rothenberg ME, Pollard JW. Postnatal mammary gland development requires macrophages and eosinophils. Development 2000;127:2269-2282.
13. Robertson SA, Mau VJ, Hudson SN, Tremellen KP. Cytokine-leukocyte networks and the establishment of pregnancy. Am J Reprod Immunol 1997;37:438-442.
14. Furuta GT, et al. Eosinophils alter colonic epithelial barrier function: role for major basic protein. Am J Physiol Gastrointest Liver Physiol 2005;289:G890-G897.
15. Yousefi S, et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med 2008;14:949-953.
16. Throsby M, Herbelin A, Pleau JM, Dardenne M. CD11c+ eosinophils in the murine thymus: developmental regulation and recruitment upon MHC class I-restricted thymocyte deletion. J Immunol 2000;165:1965-1975.
17. Chu VT, et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol 2011;12:151-159.
18. Spencer LA, Weller PF. Eosinophils and Th2 immunity: contemporary insights. Immunol Cell Biol 2010;88:250-256.
19. Shi HZ, Humbles A, Gerard C, Jin Z, Weller PF. Lymph node trafficking and antigen presentation by endobronchial eosinophils. J Clin Invest 2000;105:945-953.
20. van Rijt LS, Vos N, Hijdra D, de Vries VC, Hoogsteden HC, Lambrecht BN. Airway eosinophils accumulate in the mediastinal lymph nodes but lack antigen-presenting potential for naive T cells. J Immunol 2003;171:3372-3378.
21. Duez C, et al. Migration and accumulation of eosinophils toward regional lymph nodes after airway allergen challenge. J Allergy Clin Immunol 2004;114:820-825.
22. Del Pozo V, et al. Eosinophil as antigen-presenting cell: activation of T cell clones and T cell hybridoma by eosinophils after antigen processing. Eur J Immunol 1992;22:1919-1925.
23. Padigel UM, Lee JJ, Nolan TJ, Schad GA, Abraham D. Eosinophils can function as antigen-presenting cells to induce primary and secondary immune responses to Strongyloides stercoralis. Infect Immun 2006;74:3232-3238.
24. Shi HZ, et al. Endobronchial eosinophils preferentially stimulate T helper cell type 2 responses. Allergy 2004;59:428-435.
25. Lucey DR, Nicholson-Weller A, Weller PF. Mature human eosinophils have the capacity to express HLA-DR. Proc Natl Acad Sci USA 1989;86:1348-1351.
26. Celestin J, et al. IL-3 induces B7.2 (CD86) expression and costimulatory activity in human eosinophils. J Immunol 2001;167:6097-6104.
27. Ohkawara Y, et al. CD40 expression by human peripheral blood eosinophils. J Clin Invest 1996;97:1761-1766.
28. Yamamoto H, Sedgwick JB, Vrtis RF, Busse WW. The effect of transendothelial migration on eosinophil function. Am J Respir Cell Mol Biol 2000;23:379-388.
29. Amsen D, Blander JM, Lee GR, Tanigaki K, Honjo T, Flavell RA. Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell 2004;117:515-526.
30. Radke AL, Reynolds LE, Melo RC, Dvorak AM, Weller PF, Spencer LA. Mature human eosinophils express functional Notch ligands mediating eosinophil autocrine regulation. Blood 2009;113:3092-3101.
31. Moqbel R, Lacy P. New concepts in effector functions of eosinophil cytokines. Clin Exp Allergy 2000;30:1667-1671.
32. Kita H, Ohnishi T, Okubo Y, Weiler D, Abrams JS, Gleich GJ. Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. J Exp Med 1991;174:745-748.
33. Moqbel R, et al. Expression of mRNA and immunoreactivity for the granulocyte/macrophage colony-stimulating factor in activated human eosinophils. J Exp Med 1991;174:749-752.
34. Wong DT, et al. Human eosinophils express transforming growth factor alpha. J Exp Med 1990;172:673-681.
35. Wong DT, et al. Eosinophils from patients with blood eosinophilia express transforming growth factor beta 1. Blood 1991;78:2702-2707.
36. Ohno I, et al. Eosinophils in chronically inflamed human upper airway tissues express transforming growth factor beta 1 gene (TGF beta 1). J Clin Invest 1992;89:1662-1668.
37. Levi-Schaffer F, et al. Human eosinophils regulate human lung- and skin-derived fibroblast properties in vitro: a role for transforming growth factor beta (TGF-beta). Proc Natl Acad Sci USA 1999;96:9660-9665.
38. Burgel PR, et al. Human eosinophils induce mucin production in airway epithelial cells via epidermal growth factor receptor activation. J Immunol 2001;167:5948-5954.
39. Puxeddu I, et al. Osteopontin is expressed and functional in human eosinophils. Allergy 2010;65:168-174.
40. Puxeddu I, Alian A, Piliponsky AM, Ribatti D, Panet A, Levi-Schaffer F. Human peripheral blood eosinophils induce angiogenesis. Int J Biochem Cell Biol 2005;37:628-636.
41. Okada S, Kita H, George TJ, Gleich GJ, Leiferman KM. Migration of eosinophils through basement membrane components in vitro: role of matrix metalloproteinase-9. Am J Respir Cell Mol Biol 1997;17:519-528.
42. Kobayashi H, Gleich GJ, Butterfield JH, Kita H. Human eosinophils produce neurotrophins and secrete nerve growth factor on immunologic stimuli. Blood 2002;99:2214-2220.
43. Moqbel R, et al. Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product. J Immunol 1995;155:4939-4947.
44. Nakajima H, Gleich GJ, Kita H. Constitutive production of IL-4 and IL-10 and stimulated production of IL-8 by normal peripheral blood eosinophils. J Immunol 1996;156:4859-4866.
45. Nonaka M, et al. Distinct immunohistochemical localization of IL-4 in human inflamed airway tissues. IL-4 is localized to eosinophils in vivo and is released by peripheral blood eosinophils. J Immunol 1995;155:3234-3244.
46. Bandeira-Melo C, Sugiyama K, Woods LJ, Weller PF. Cutting edge: eotaxin elicits rapid vesicular transport-mediated release of preformed IL-4 from human eosinophils. J Immunol 2001;166:4813-4817.
47. Melani C, et al. Interleukin-6 expression in human neutrophil and eosinophil peripheral blood granulocytes. Blood 1993;81:2744-2749.
48. Hamid Q, et al. Human eosinophils synthesize and secrete interleukin-6, in vitro. Blood 1992;80:1496-1501.
49. Costa JJ, et al. Human eosinophils can express the cytokines tumor necrosis factor-alpha and macrophage inflammatory protein-1 alpha. J Clin Invest 1993;91:2673-2684.
50. Lacy P, et al. Rapid mobilization of intracellularly stored RANTES in response to interferon-gamma in human eosinophils. Blood 1999;94:23-32.
51. Kobayashi T, Iijima K, Kita H. Marked airway eosinophilia prevents development of airway hyper-responsiveness during an allergic response in IL-5 transgenic mice. J Immunol 2003;170:5756-5763.
52. Terness P, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2, 3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 2002;196:447-457.
53. Odemuyiwa SO, et al. Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2, 3-dioxygenase. J Immunol 2004;173:5909-5913.
54. Yang D, Rosenberg HF, Chen Q, Dyer KD, Kurosaka K, Oppenheim JJ. Eosinophil-derived neurotoxin (EDN), an antimicrobial protein with chemotactic activities for dendritic cells. Blood 2003;102:3396-3403.
55. Yang D, et al. Human ribonuclease A superfamily members, eosinophil-derived neurotoxin and pancreatic ribonuclease, induce dendritic cell maturation and activation. J Immunol 2004;173:6134-6142.
56. Yang D, et al. Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. J Exp Med 2008;205:79-90.
57. Sabin EA, Kopf MA, Pearce EJ. Schistosoma mansoni egg-induced early IL-4 production is dependent upon IL-5 and eosinophils. J Exp Med 1996;184:1871-1878.
58. Voehringer D, Shinkai K, Locksley RM. Type 2 immunity reflects orchestrated recruitment of cells committed to IL-4 production. Immunity 2004;20:267-277.
59. Voehringer D, Reese TA, Huang X, Shinkai K, Locksley RM. Type 2 immunity is controlled by IL-4/IL-13 expression in hematopoietic non-eosinophil cells of the innate immune system. J Exp Med 2006;203:1435-1446.
60. Shinkai K, Mohrs M, Locksley RM. Helper T cells regulate type-2 innate immunity in vivo. Nature 2002;420:825-829.
61. Sabin EA, Pearce EJ. Early IL-4 production by non-CD4+ cells at the site of antigen deposition predicts the development of a T helper 2 cell response to Schistosoma mansoni eggs. J Immunol 1995;155:4844-4853.
62. Mattes J, et al. Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J Exp Med 2002;195:1433-1444.
63. Lee JJ, et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 2004;305:1773-1776.
64. Walsh ER, et al. Strain-specific requirement for eosinophils in the recruitment of T cells to the lung during the development of allergic asthma. J Exp Med 2008;205:1285-1292.
65. Jacobsen EA, et al. Allergic pulmonary inflammation in mice is dependent on eosinophil-induced recruitment of effector T cells. J Exp Med 2008;205:699-710.
66. Fulkerson PC, Fischetti CA, McBride ML, Hassman LM, Hogan SP, Rothenberg ME. A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation. Proc Natl Acad Sci USA 2006;103:16418-16423.
67. Oxvig C, Gleich GJ, Sottrup-Jensen L. Localization of disulfide bridges and free sulfhydryl groups in human eosinophil granule major basic protein. FEBS Lett 1994;341:213-217.
68. Swaminathan GJ, et al. Crystal structure of the eosinophil major basic protein at 1.8 A. An atypical lectin with a paradigm shift in specificity. J Biol Chem 2001;276:26197-26203.
69. Popken-Harris P, et al. Expression, purification, and characterization of the recombinant proform of eosinophil granule major basic protein. J Immunol 1995;155:1472-1480.
70. Abu-Ghazaleh RI, Gleich GJ, Prendergast FG. Interaction of eosinophil granule major basic protein with synthetic lipid bilayers: a mechanism for toxicity. J Membr Biol 1992;128:153-164.
71. Plager DA, et al. A novel and highly divergent homolog of human eosinophil granule major basic protein. J Biol Chem 1999;274:14464-14473.
72. Boix E. Eosinophil cationic protein. Methods Enzymol 2001;341:287-305.
73. Domachowske JB, Dyer KD, Adams AG, Leto TL, Rosenberg HF. Eosinophil cationic protein/RNase 3 is another RNase A-family ribonuclease with direct antiviral activity. Nucleic Acids Res 1998;26:3358-3363.
74. Rosenberg HF, Domachowske JB. Eosinophils, eosinophil ribonucleases, and their role in host defense against respiratory virus pathogens. J Leukoc Biol 2001;70:691-698.
75. Rosenberg HF, Domachowske JB. Eosinophil-derived neurotoxin. Methods Enzymol 2001;341:273-286.
76. Gleich GJ, Loegering DA, Bell MP, Checkel JL, Ackerman SJ, McKean DJ. Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. Proc Natl Acad Sci USA 1986;83:3146-3150.
77. Domachowske JB, Dyer KD, Bonville CA, Rosenberg HF. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis 1998;177:1458-1464.
78. Adamko DJ, Yost BL, Gleich GJ, Fryer AD, Jacoby DB. Ovalbumin sensitization changes the inflammatory response to subsequent Eosinophils mediate airway hyperresponsiveness, m(2) muscarinic receptor dysfunction, and antiviral effects parainfluenza infection. J Exp Med 1999;190:1465-1478.
79. van Dalen CJ, Kettle AJ. Substrates and products of eosinophil peroxidase. Biochem J 2001;358:233-239.
80. Mitra SN, Slungaard A, Hazen SL. Role of eosinophil peroxidase in the origins of protein oxidation in asthma. Redox Rep 2000;5:215-224.
81. Wu W, et al. Eosinophils generate brominating oxidants in allergen-induced asthma. J Clin Invest 2000;105:1455-1463.
82. MacPherson JC, et al. Eosinophils are a major source of nitric oxide-derived oxidants in severe asthma: characterization of pathways available to eosinophils for generating reactive nitrogen species. J Immunol 2001;166:5763-5772.
83. Gleich GJ, Adolphson CR, Kita H. The eosinophil and asthma. In: Busse WW, Holgate ST, eds. Asthma and rhinitis. 2nd edn. Oxford, UK: Blackwell Science, 2000;429-479.
84. Gleich GJ, Fryer AD, Jacoby DB. Eosinophil granule proteins and bronchial hyperreactivity. In: Holgate ST, et al. eds. Asthma: Physiology, immunopharmacology, and treatment. London: Academic Press, 1993:119-129.
85. Gleich GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 2000;105:651-663.
86. Ponikau JU, et al. Striking deposition of toxic eosinophil major basic protein in mucus: implications for chronic rhinosinusitis. J Allergy Clin Immunol 2005;116:362-369.
87. Gundel RH, Letts LG, Gleich GJ. Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. J Clin Invest 1991;87:1470-1473.
88. Costello RW, Schofield BH, Kephart GM, Gleich GJ, Jacoby DB, Fryer AD. Localization of eosinophils to airway nerves and effect on neuronal M2 muscarinic receptor function. Am J Physiol 1997;273:L93-L103.
89. Costello RW, et al. Antigen-induced hyperreactivity to histamine: role of the vagus nerves and eosinophils. Am J Physiol 1999;276:L709-L714.
90. Kephart GM, et al. Marked deposition of eosinophil-derived neurotoxin in adult patients with eosinophilic esophagitis. Am J Gastroenterol 2010;105:298-307.
91. Straumann A, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 2010;59:21-30.
92. Dennis EA, Rhee SG, Billah MM, Hannun YA. Role of phospholipase in generating lipid second messengers in signal transduction. FASEB J 1991;5:2068-2077.
93. Sugiura T, et al. Synthesis and action of PAF in human eosinophils. J Lipid Mediat 1992;5:151-153.
94. Stahle-Backdahl M, Sudbeck BD, Eisen AZ, Welgus HG, Parks WC. Expression of 92-kDa type IV collagenase mRNA by eosinophils associated with basal cell carcinoma. J Invest Dermatol 1992;99:497-503.
95. Stahle-Backdahl M, Parks WC. 92-kd gelatinase is actively expressed by eosinophils and stored by neutrophils in squamous cell carcinoma. Am J Pathol 1993;142:995-1000.
96. Stahle-Backdahl M, Inoue M, Guidice GJ, Parks WC. 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. J Clin Invest 1994;93:2022-2030.
97. Kumagai K, et al. Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. J Immunol 1999;162:4212-4219.
98. Rothenberg ME, et al. Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. J Clin Invest 1988;81:1986-1992.
99. Winqvist I, Olofsson T, Olsson I, Persson AM, Hallberg T. Altered density, metabolism and surface receptors of eosinophils in eosinophilia. Immunology 1982;47:531-539.
100. Fukuda T, Dunnette SL, Reed CE, Ackerman SJ, Peters MS, Gleich GJ. Increased numbers of hypodense eosinophils in the blood of patients with bronchial asthma. Am Rev Respir Dis 1985;132:981-985.
101. Lopez AF, et al. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest 1986;78:1220-1228.
102. Lopez AF, Sanderson CJ, Gamble JR, Campbell HD, Young IG, Vadas MA. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med 1988;167:219-224.
103. Ingley E, Young IG. Characterization of a receptor for interleukin-5 on human eosinophils and the myeloid leukemia line HL-60. Blood 1991;78:339-344.
104. Migita M, et al. Characterization of the human IL-5 receptors on eosinophils. Cell Immunol 1991;133:484-497.
105. Warringa RA, Schweizer RC, Maikoe T, Kuijper PH, Bruijnzeel PL, Koendermann L. Modulation of eosinophil chemotaxis by interleukin-5. Am J Respir Cell Mol Biol 1992;7:631-636.
106. Schweizer RC, Welmers BA, Raaijmakers JA, Zanen P, Lammers JW, Koenderman L. RANTES- and interleukin-8-induced responses in normal human eosinophils: effects of priming with interleukin-5. Blood 1994;83:3697-3704.
107. Kita H, Weiler DA, Abu-Ghazaleh R, Sanderson CJ, Gleich GJ. Release of granule proteins from eosinophils cultured with IL-5. J Immunol 1992;149:629-635.
108. Kita H, Adolphson CR, Gleich GJ. Biology of eosinophils. In: Adkinson NF, et al. eds. Middleton's Allergy: Principles and Practice. 6th edn. St. Louis: Mosby, 2003:305-332.
109. Bracke M, et al. Differential effects of the T helper cell type 2-derived cytokines IL-4 and IL-5 on ligand binding to IgG and IgA receptors expressed by human eosinophils. J Immunol 1997;159:1459-1465.
110. Luttmann W, Matthiesen T, Matthys H, Virchow JC Jr. Synergistic effects of interleukin-4 or interleukin-13 and tumor necrosis factor-alpha on eosinophil activation in vitro. Am J Respir Cell Mol Biol 1999;20:474-480.
111. Temann UA, Geba GP, Rankin JA, Flavell RA. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med 1998;188:1307-1320.
112. Gounni AS, et al. Interleukin-9 enhances interleukin-5 receptor expression, differentiation, and survival of human eosinophils. Blood 2000;96:2163-2171.
113. Valerius T, Repp R, Kalden JR, Platzer E. Effects of IFN on human eosinophils in comparison with other cytokines. A novel class of eosinophil activators with delayed onset of action. J Immunol 1990;145:2950-2958.
114. Hansel TT, et al. Induction and function of eosinophil intercellular adhesion molecule-1 and HLA-DR. J Immunol 1992;149:2130-2136.
115. Saenz SA, Taylor BC, Artis D. Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. Immunol Rev 2008;226:172-190.
116. Wong CK, Hu S, Cheung PF, Lam CW. Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: implications in allergic inflammation. Am J Respir Cell Mol Biol 2010;43:305-315.
117. Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol 2008;121:1484-1490.
118. Sillaber C, et al. Type beta transforming growth factors promote interleukin-3 (IL-3)-dependent differentiation of human basophils but inhibit IL-3-dependent differentiation of human eosinophils. Blood 1992;80:634-641.
119. Alam R, Forsythe P, Stafford S, Fukuda Y. Transforming growth factor beta abrogates the effects of hematopoietins on eosinophils and induces their apoptosis. J Exp Med 1994;179:1041-1045.
120. Nakajima H, Sano H, Nishimura T, Yoshida S, Iwamoto I. Role of vascular cell adhesion molecule 1/very late activation antigen 4 and intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 interactions in antigen-induced eosinophil and T cell recruitment into the tissue. J Exp Med 1994;179:1145-1154.
121. Fulkerson PC, et al. Negative regulation of eosinophil recruitment to the lung by the chemokine monokine induced by IFN-gamma (Mig, CXCL9). Proc Natl Acad Sci USA 2004;101:1987-1992.
122. Zielinski RM, Lawrence WD. Interferon-alpha for the hypereosinophilic syndrome. Ann Intern Med 1990;113:716-718.
123. Nutku E, Aizawa H, Hudson SA, Bochner BS. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 2003;101:5014-5020.
124. Nutku-Bilir E, Hudson SA, Bochner BS. Interleukin-5 priming of human eosinophils alters siglec-8 mediated apoptosis pathways. Am J Respir Cell Mol Biol 2008;38:121-124.
125. Guo JP, et al. Characterization of expression of glycan ligands for siglec-f in normal mouse lungs. Am J Respir Cell Mol Biol 2011;44:238-243.
126. Weller PF, Rand TH, Barrett T, Elovic A, Wong DT, Finberg RW. Accessory cell function of human eosinophils. HLA-DR-dependent, MHC-restricted antigen-presentation and IL-1 alpha expression. J Immunol 1993;150:2554-2562.
127. Hartnell A, Robinson DS, Kay AB, Wardlaw AJ. CD69 is expressed by human eosinophils activated in vivo in asthma and in vitro by cytokines. Immunology 1993;80:281-286.
128. Rand TH, Silberstein DS, Kornfeld H, Weller PF. Human eosinophils express functional interleukin 2 receptors. J Clin Invest 1991;88:825-832.
129. Hartnell A, Kay AB, Wardlaw AJ. Interleukin-3-induced up-regulation of CR3 expression on human eosinophils is inhibited by dexamethasone. Immunology 1992;77:488-493.
130. Mawhorter SD, Stephany DA, Ottesen EA, Nutman TB. Identification of surface molecules associated with physiologic activation of eosinophils. Application of whole-blood flow cytometry to eosinophils. J Immunol 1996;156:4851-4858.
131. Hansel TT, et al. Sputum eosinophils from asthmatics express ICAM-1 and HLA-DR. Clin Exp Immunol 1991;86:271-277.
132. Sedgwick JB, Calhoun WJ, Vrtis RF, Bates ME, McAllister PK, Busse WW. Comparison of airway and blood eosinophil function after in vivo antigen challenge. J Immunol 1992;149:3710-3718.
133. Mengelers HJ, Maikoe T, Brinkman L, Hooibrink B, Lammers JW, Koenderman L. Immunophenotyping of eosinophils recovered from blood and BAL of allergic asthmatics. Am J Respir Crit Care Med 1994;149:345-351.
134. Bochner BS. Systemic activation of basophils and eosinophils: markers and consequences. J Allergy Clin Immunol 2000;106:S292-S302.
135. Johansson MW, Kelly EA, Busse WW, Jarjour NN, Mosher DF. Up-regulation and activation of eosinophil integrins in blood and airway after segmental lung antigen challenge. J Immunol 2008;180:7622-7635.
136. Grutters JC, Brinkman L, Aslander MM, van den Bosch JM, Koenderman L, Lammers JW. Asthma therapy modulates priming-associated blood eosinophil responsiveness in allergic asthmatics. Eur Respir J 1999;14:915-922.
137. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-216.
138. Plotz SG, et al. The interaction of human peripheral blood eosinophils with bacterial lipopolysaccharide is CD14 dependent. Blood 2001;97:235-241.
139. Sabroe I, Jones EC, Usher LR, Whyte MK, Dower SK. Toll-like receptor (TLR)2 and TLR4 in human peripheral blood granulocytes: a critical role for monocytes in leukocyte lipopolysaccharide responses. J Immunol 2002;168:4701-4710.
140. Nagase H, et al. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J Immunol 2003;171:3977-3982.
141. Cirino G, Vergnolle N. Proteinase-activated receptors (PARs): crossroads between innate immunity and coagulation. Curr Opin Pharmacol 2006;6:428-434.
142. Shpacovitch V, Feld M, Bunnett NW, Steinhoff M. Protease-activated receptors: novel PARtners in innate immunity. Trends Immunol 2007;28:541-550.
143. Miike S, McWilliam AS, Kita H. Trypsin induces activation and inflammatory mediator release from human eosinophils through protease-activated receptor-2. J Immunol 2001;167:6615-6622.
144. Miike S, Kita H. Human eosinophils are activated by cysteine proteases and release inflammatory mediators. J Allergy Clin Immunol 2003;111:704-713.
145. Matsuwaki Y, et al. Recognition of fungal protease activities induces cellular activation and eosinophil-derived neurotoxin release in human eosinophils. J Immunol 2009;183:6708-6716.
146. Wada K, et al. Inflammatory responses of human eosinophils to cockroach are mediated through protease-dependent pathways. J Allergy Clin Immunol 2010;126:169-172.
147. Bush RK, Prochnau JJ. Alternaria-induced asthma. J Allergy Clin Immunol 2004;113:227-234.
148. O'Hollaren MT, et al. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. N Engl J Med 1991;324:359-363.
149. Kheradmand F, Kiss A, Xu J, Lee SH, Kolattukudy PE, Corry DB. A protease-activated pathway underlying Th cell type 2 activation and allergic lung disease. J Immunol 2002;169:5904-5911.
150. Inoue Y, Matsuwaki Y, Shin SH, Ponikau JU, Kita H. Nonpathogenic, environmental fungi induce activation and degranulation of human eosinophils. J Immunol 2005;175:5439-5447.
151. Yoon J, Ponikau JU, Lawrence CB, Kita H. Innate antifungal immunity of human eosinophils mediated by a beta 2 integrin, CD11b. J Immunol 2008;181:2907-2915.
152. Dichmann S, et al. Adenosine triphosphate-induced oxygen radical production and CD11b up-regulation: Ca(++) mobilization and actin reorganization in human eosinophils. Blood 2000;95:973-978.
153. Idzko M, et al. Functional characterization of P2Y and P2X receptors in human eosinophils. J Cell Physiol 2001;188:329-336.
154. Hirai H, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001;193:255-261.
155. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007;81:1-5.
156. Rock KL, Kono H. The inflammatory response to cell death. Annu Rev Pathol 2008;3:99-126.
157. Kobayashi T, Kouzaki H, Kita H. Human eosinophils recognize endogenous danger signal crystalline uric acid and produce proinflammatory cytokines mediated by autocrine ATP. J Immunol 2010;184:6350-6358.
158. Lotfi R, et al. Eosinophils oxidize damage-associated molecular pattern molecules derived from stressed cells. J Immunol 2009;183:5023-5031.
159. Wang HB, Weller PF. Pivotal advance: eosinophils mediate early alum adjuvant-elicited B cell priming and IgM production. J Leukoc Biol 2008;83:817-821.
160. Abu-Ghazaleh RI, Fujisawa T, Mestecky J, Kyle RA, Gleich GJ. IgA-induced eosinophil degranulation. J Immunol 1989;142:2393-2400.
161. Dunne DW, Richardson BA, Jones FM, Clark M, Thorne KJ, Butterworth AE. The use of mouse/human chimaeric antibodies to investigate the roles of different antibody isotypes, including IgA2, in the killing of Schistosoma mansoni schistosomula by eosinophils. Parasite Immunol 1993;15:181-185.
162. Monteiro RC, Hostoffer RW, Cooper MD, Bonner JR, Gartland GL, Kubagawa H. Definition of immunoglobulin A receptors on eosinophils and their enhanced expression in allergic individuals. J Clin Invest 1993;92:1681-1685.
163. Lamkhioued B, Gounni AS, Gruart V, Pierce A, Capron A, Capron M. Human eosinophils express a receptor for secretory component. Role in secretory IgA-dependent activation. Eur J Immunol 1995;25:117-125.
164. Motegi Y, Kita H. Interaction with secretory component stimulates effector functions of human eosinophils but not of neutrophils. J Immunol 1998;161:4340-4346.
165. van de Winkel JG, Capel PJ. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 1993;14:215-221.
166. Moqbel R, et al. The effect of platelet-activating factor on IgE binding to, and IgE-dependent biological properties of, human eosinophils. Immunology 1990;70:251-257.
167. Truong MJ, Gruart V, Liu FT, Prin L, Capron A, Capron M. IgE-binding molecules (Mac-2/epsilon BP) expressed by human eosinophils. Implication in IgE-dependent eosinophil cytotoxicity. Eur J Immunol 1993;23:3230-3235.
168. Gounni AS, et al. High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature 1994;367:183-186.
169. Seminario MC, Saini SS, MacGlashan DW Jr, Bochner BS. Intracellular expression and release of Fc epsilon RI alpha by human eosinophils. J Immunol 1999;162:6893-6900.
170. Kita H, et al. Does IgE bind to and activate eosinophils from patients with allergy? J Immunol 1999;162:6901-6911.
171. Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, Dahinden CA. RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med 1992;176:1489-1495.
172. Alam R, et al. RANTES is a chemotactic and activating factor for human eosinophils. J Immunol 1993;150:3442-3448.
173. Kita H, Abu-Ghazaleh RI, Sur S, Gleich GJ. Eosinophil major basic protein induces degranulation and IL-8 production by human eosinophils. J Immunol 1995;154:4749-4758.
174. Daffern PJ, Pfeifer PH, Ember JA, Hugli TE. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med 1995;181:2119-2127.
175. Kernen P, et al. Shape changes, exocytosis, and cytosolic free calcium changes in stimulated human eosinophils. J Clin Invest 1991;87:2012-2017.
176. Dyer KD, et al. Mouse and human eosinophils degranulate in response to platelet-activating factor (PAF) and lysoPAF via a PAF-receptor-independent mechanism: evidence for a novel receptor. J Immunol 2010;184:6327-6334.
177. Bartemes KR, McKinney S, Gleich GJ, Kita H. Endogenous platelet-activating factor is critically involved in effector functions of eosinophils stimulated with IL-5 or IgG. J Immunol 1999;162:2982-2989.
178. Kato M, et al. Platelet-activating factor activates two distinct effector pathways in human eosinophils. J Immunol 2002;169:5252-5259.
179. Kaneko M, Horie S, Kato M, Gleich GJ, Kita H. A crucial role for beta 2 integrin in the activation of eosinophils stimulated by IgG. J Immunol 1995;155:2631-2641.
180. Horie S, Kita H. CD11b/CD18 (Mac-1) is required for degranulation of human eosinophils induced by human recombinant granulocyte-macrophage colony-stimulating factor and platelet-activating factor. J Immunol 1994;152:5457-5467.
181. Kato M, Abraham RT, Okada S, Kita H. Ligation of the beta2 integrin triggers activation and degranulation of human eosinophils. Am J Respir Cell Mol Biol 1998;18:675-686.
182. Nagata M, Sedgwick JB, Kita H, Busse WW. Granulocyte macrophage colony-stimulating factor augments ICAM-1 and VCAM-1 activation of eosinophil function. Am J Respir Cell Mol Biol 1998;19:158-166.
183. Wegner CD, Gundel RH, Churchill L. Adhesion Glycoproteins as Regulators of Airway Inflammation: Emphasis on the Role of ICAM-1. London: Academic Press, 1993.
184. Yoon J, Terada A, Kita H. CD66b regulates adhesion and activation of human eosinophils. J Immunol 2007;179:8454-8462.
185. Waterston RH, et al. Initial sequencing and comparative analysis of the mouse genome. Nature 2002;420:520-562.
186. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004;172:2731-2738.
187. Rosenberg HF. The eosinophil ribonucleases. Cell Mol Life Sci 1998;54:795-803.
188. Borchers MT, et al. In vitro assessment of chemokine receptor-ligand interactions mediating mouse eosinophil migration. J Leukoc Biol 2002;71:1033-1041.
189. Stelts D, et al. Eosinophils retain their granule major basic protein in a murine model of allergic pulmonary inflammation. Am J Respir Cell Mol Biol 1998;18:463-470.
190. Denzler KL, et al. Extensive eosinophil degranulation and peroxidase-mediated oxidation of airway proteins do not occur in a mouse ovalbumin-challenge model of pulmonary inflammation. J Immunol 2001;167:1672-1682.
191. Behm CA, Ovington KS. The role of eosinophils in parasitic helminth infections: insights from genetically modified mice. Parasitol Today 2000;16:202-209.
192. Meeusen EN, Balic A. Do eosinophils have a role in the killing of helminth parasites? Parasitol Today 2000;16:95-101.
193. Sher A, Coffman RL, Hieny S, Cheever AW. Ablation of eosinophil and IgE responses with anti-IL-5 or anti-IL-4 antibodies fails to affect immunity against Schistosoma mansoni in the mouse. J Immunol 1990;145:3911-3916.
194. Herndon FJ, Kayes SG. Depletion of eosinophils by anti-IL-5 monoclonal antibody treatment of mice infected with Trichinella spiralis does not alter parasite burden or immunologic resistance to reinfection. J Immunol 1992;149:3642-3647.
195. Takamoto M, Ovington KS, Behm CA, Sugane K, Young IG, Matthaei KI. Eosinophilia, parasite burden and lung damage in Toxocara canis infection in C57Bl/6 mice genetically deficient in IL-5. Immunology 1997;90:511-517.
196. Le Goff L, Loke P, Ali HF, Taylor DW, Allen JE. Interleukin-5 is essential for vaccine-mediated immunity but not innate resistance to a filarial parasite. Infect Immun 2000;68:2513-2517.
197. Swartz JM, et al. Schistosoma mansoni infection in eosinophil lineage-ablated mice. Blood 2006;108:2420-2427.
198. Korenaga M, Hitoshi Y, Yamaguchi N, Sato Y, Takatsu K, Tada I. The role of interleukin-5 in protective immunity to Strongyloides venezuelensis infection in mice. Immunology 1991;72:502-507.
199. Yoshida T, et al. Defective B-1 cell development and impaired immunity against Angiostrongylus cantonensis in IL-5R alpha-deficient mice. Immunity 1996;4:483-494.
200. Pearce EJ, Sher A. Functional dichotomy in the CD4+ T cell response to Schistosoma mansoni. Exp Parasitol 1991;73:110-116.
201. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008;454:428-435.